Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

Clinical Infectious Diseases

Volumn 46, Issue 9, 2008, Pages 1455-1457

  Shapira, Michael Y ^a   Resnick, Igor B ^a   Chou, Sunwen ^c   Neumann, Avidan U ^b   Lurain, Nell S ^d   Stamminger, Thomas ^e   Caplan, Orit ^a   Saleh, Niveen ^a   Efferth, Thomas ^f   Marschall, Manfred ^e   Wolf, Dana G ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; CASE REPORT; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; ARTEMISININS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FOSCARNET; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; TREATMENT OUTCOME;

EID: 42549168601     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587106     Document Type: Article

References (12)

1. Boeckh M, Fries B, Nichols WG. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 2004; 8(Suppl 5):19-27.
2. Wolf DG, Lurain NS, Zuckerman T, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 2003; 101:463-5.
3. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873-83.
4. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol 2004; 65:403-9.
5. Scott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007; 51:89-94.
6. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003; 47:1334-42.
7. Efferth T, Marschall M, Wang X, et al. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med 2002; 80:233-42.
8. Kaptein SJ, Efferth T, Leis M, et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res 2006; 69:60-9.
9. Boeckh M, Huang M, Ferrenberg J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42:1142-8.
10. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190:177-82.
11. Marfori JE, Exner MM, Marousek GI, Chou S, Drew WL. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007; 38:120-5.
12. Neumann AU, Lam N, Dahari H, Gretch DR, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282:103-7.